Phathom Pharmaceuticals announced strong Q3 2026 financial results with net revenues of $84.7 million, a 71% increase year-over-year, and positive operating cash flow for the second consecutive quarter. The company highlighted commercial progress with over 2 million VOQUEZNA prescriptions filled, driven by initiatives improving access and physician prescribing. Clinical developments include a Phase 3 study for VOQUEZNA's as-needed use in Non-Erosive GERD and upcoming Phase 2 trial results for Eosinophilic Esophagitis. Phathom reaffirmed its full-year 2026 financial guidance and remains confident in its financial position and growth prospects.
Phathom Pharmaceuticals' Q3 2026 financial results are reported here with Pluang's health sector market data as of Oct 29, 2026 17:11 WIB: Out of 150 priced health-sector US stocks tradable on Pluang, 86 rose and 57 fell today. Notable movers include IOVA at USD 16.12 with a 1-day change of +8.85% and 100% sell order activity, BFLY at USD 8.32 up 6.53%, and NUWE at USD 5.87 up 5.48%. The most notable figure is IOVA's 100% sell order activity on Pluang.
Naples Comprehensive Health (NCH) has completed the first tricuspid valve repair in the US using the PASCAL Precision system following FDA approval. This minimally invasive catheter-based procedure offers a new treatment option for patients with seve...
Immunocore Holdings will present Phase 1/2 clinical trial data for brenetafusp alone and combined with KIMMTRAK in treating metastatic uveal melanoma at the 2026 Society for Immunotherapy of Cancer meeting. This trial evaluates safety and efficacy in...
Collegium Pharmaceutical and Boston Legacy FC have extended their partnership to include youth coach training, an annual Sports for All Summit, and sensory inclusion programs aimed at supporting neurodivergent children, especially those with ADHD, in...
Gilat Satellite Networks announced that its CEO Adi Sfadia and CFO Gil Benyamini will attend the Deutsche Bank Global Space and Defense Tech Summit on November 18, 2026, in New York City. The event will feature one-on-one and group meetings, providin...
Boralex Inc. has acquired Wind2, a UK-based renewable energy developer with about 350 MW of advanced wind projects across Scotland, England, and Wales. This acquisition strengthens Boralex's presence and capabilities in the UK, aligning with its stra...
